Jérusalem

BrainsWay Reports Preliminary Record Fourth Quarter Revenue and Full-Year 2020 Financial Results

Retrieved on: 
Tuesday, February 16, 2021

(NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced certain preliminary unaudited Fourth Quarter Financial Results.

Key Points: 
  • (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced certain preliminary unaudited Fourth Quarter Financial Results.
  • As of December 31, 2020, BrainsWays Deep TMS installed base was 629 total systems after adding 36 systems during the fourth quarter, representing an increase of 18.7% compared to prior year results.
  • These preliminary results should not be viewed as a substitute for the Companys fourth quarter reviewed and year end audited consolidated financial statements prepared in accordance with IFRS.
  • Such statements may be preceded by the words intends, may, will, plans, expects, anticipates, projects, predicts, estimates, aims, believes, hopes, potential or similar words, and include statements regarding preliminary financial results for the fourth quarter revenue and full-year 2020 financial results.

LipoMedix Announces Manufacturing Agreement with ForDoz for Promitil®

Retrieved on: 
Wednesday, February 10, 2021

We continue to move full-steam ahead, knowing that the patients we can help with Promitil have been long awaiting a lower-toxicity and effective treatment option, said Dr. Alberto Gabizon, President and Chief Scientific Officer of LipoMedix.

Key Points: 
  • We continue to move full-steam ahead, knowing that the patients we can help with Promitil have been long awaiting a lower-toxicity and effective treatment option, said Dr. Alberto Gabizon, President and Chief Scientific Officer of LipoMedix.
  • We are thinking long term when selecting our partnerships and look forward to partnering with ForDoz as we move toward Phase II studies to move the development of Promitil forward.
  • By leveraging ForDozs drug delivery technology and experience, LipoMedix expects to be able to effectively troubleshoot the many industry-wide challenges of product development and manufacturing of nanotechnology.
  • ForDoz has a proven track record in manufacturing and in successful commercialization, said Sanjeev Luther, Executive Chairman of the Board of LipoMedix.

Entera Bio Initiates New Research Program For Oral GLP-2

Retrieved on: 
Monday, February 8, 2021

& JERUSALEM, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced a new research program for an oral glucagon-like peptide-2 (GLP-2) analog based on the Companys platform technology.

Key Points: 
  • & JERUSALEM, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced a new research program for an oral glucagon-like peptide-2 (GLP-2) analog based on the Companys platform technology.
  • In preclinical models, Enteras oral formulation of a GLP-2 analog has shown a comparable pharmacokinetic profile to a subcutaneous injection.
  • Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

RenalSense Announces Distribution Agreement in Israel with Medtechnica

Retrieved on: 
Monday, January 25, 2021

JERUSALEM, Jan. 25, 2021 /PRNewswire/ --RenalSense, a leading company in real-time renal diagnostics, today announced a distribution agreement with Medtechnica, Israel's largest distributor of medical equipment and health services.Medtechnica will market RenalSense's Clarity RMScritical care monitoring system to hospitals throughout Israel.

Key Points: 
  • JERUSALEM, Jan. 25, 2021 /PRNewswire/ --RenalSense, a leading company in real-time renal diagnostics, today announced a distribution agreement with Medtechnica, Israel's largest distributor of medical equipment and health services.Medtechnica will market RenalSense's Clarity RMScritical care monitoring system to hospitals throughout Israel.
  • RenalSense is currently in discussions with additional partners regarding distribution agreements for other key markets.
  • Medtechnica, founded in 1953, is the largest distributor of medical equipment and health services in Israel.
  • Manufacturers represented by Medtechnica include Fresenius Kabi, Philips, Boston Scientific, Getinge, Masimo, Hologic, Elekta, J&J, Hill-Rom among other blue chip companies.

BrainsWay Signs Exclusive Distribution Agreement with Gaelan Medical Trade LLC

Retrieved on: 
Monday, January 25, 2021

(NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, announced an exclusive distribution agreement with Gaelan Medical Trade LLC (Gaelan), a leading healthcare company with extensive distribution channels in the United Arab Emirates (UAE).

Key Points: 
  • (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, announced an exclusive distribution agreement with Gaelan Medical Trade LLC (Gaelan), a leading healthcare company with extensive distribution channels in the United Arab Emirates (UAE).
  • It is truly a privilege to have this new opportunity to work with Galean in order to expand access to this lifesaving technology.
  • We are eager to begin distribution of BrainsWays important technology to help improve mental health and transform lives.
  • Gaelan Medical, with its experienced management team, caters to diverse healthcare needs including, pharmaceuticals, medical consumables, medical equipment and beauty products.

Innocan Pharma Announces Successful Production of CBD Loaded Liposomes under Aseptic Conditions

Retrieved on: 
Friday, January 22, 2021

Dr. Ahuva Cern, the project manager in Professor Barenholz's laboratory at the Hebrew University, Jerusalem, stated: "We succeeded in manufacturing CBD-loaded Liposomes under aseptic conditions.

Key Points: 
  • Dr. Ahuva Cern, the project manager in Professor Barenholz's laboratory at the Hebrew University, Jerusalem, stated: "We succeeded in manufacturing CBD-loaded Liposomes under aseptic conditions.
  • Those liposomes loaded with CBD were found to be sterile and conform to the pyrogenicity limits.
  • This achievement is a 'must' step as we are looking forward to large scale production and later commercial size production."
  • The founders and officers of Innocan Israel have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

Entera Bio Issues Letter to Shareholders

Retrieved on: 
Monday, January 11, 2021

BOSTON and JERUSALEM, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to Shareholders from Spiros Jamas, Sc.D, its newly appointed Chief Executive Officer and a member of its Board of Directors.

Key Points: 
  • BOSTON and JERUSALEM, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to Shareholders from Spiros Jamas, Sc.D, its newly appointed Chief Executive Officer and a member of its Board of Directors.
  • Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com .
  • There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis

Retrieved on: 
Thursday, December 10, 2020

EB613 is positioned as the first potential drug candidate that could provide a patient friendly, once daily, oral, bone building (anabolic) treatment for osteoporosis patients.

Key Points: 
  • EB613 is positioned as the first potential drug candidate that could provide a patient friendly, once daily, oral, bone building (anabolic) treatment for osteoporosis patients.
  • There is a clear and compelling need for an oral PTH treatment that builds bone in patients with osteoporosis.
  • EB613 is an orally delivered human parathyroid hormone (1-34), or PTH, drug candidate positioned as the first potential once daily, oral, bone building (anabolic) treatment for osteoporosis patients.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Entera Bio Appoints Spiros Jamas as Chief Executive Officer

Retrieved on: 
Monday, November 30, 2020

to the role of Chief Executive Officer and a member of the Board of Directors effective January 4, 2021.

Key Points: 
  • to the role of Chief Executive Officer and a member of the Board of Directors effective January 4, 2021.
  • Dr. Garceau will continue to serve as a Director of Entera Bio.
  • Spiros Jamas is a biotech entrepreneur with over 30 years of senior management experience in the biopharmaceutical industry.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Entera Bio Ltd Announces Third Quarter 2020 Financial Results and Provides Clinical Update

Retrieved on: 
Thursday, November 19, 2020

ET

Key Points: 
  • ET
    BOSTON and JERUSALEM, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced financial and operating results for the quarter ended September 30, 2020 and provided a clinical update on EB613, its lead, orally delivered product candidate for the treatment of osteoporosis.
  • The Phase 2 clinical trial is a dose-ranging, placebo-controlled, study in postmenopausal female subjects with osteoporosis, or low BMD.
  • At September 30, 2020, Entera had cash and cash equivalents of $7.1 million, compared to $15.2 million at December 31, 2019.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.